Equities
Health CareMedical Equipment and Services
  • Price (HKD)3.66
  • Today's Change0.00 / 0.00%
  • Shares traded--
  • 1 Year change-43.61%
  • Beta1.1231
Data delayed at least 15 minutes, as of Mar 28 2024.
More ▼
Improved Notifications for Markets Data Alerts
Improved Notifications for Markets Data Alerts
Want push notifications sent directly to your devices for equity price changes and breaking news stories? Let us know here.
 
Existing alertsView our existing alerts
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Peijia Medical Ltd is a China-based holding company mainly engaged in the research and development of interventional procedural medical devices. Through its subsidiaries, the Company operates two segments. Transcatheter Valve Therapeutic Business segment is mainly engaged in the development of transcatheter valve therapeutic medical devices. Neurointerventional Business segment is engaged in the research and development of neurointerventional procedural medical devices. The Company's main products under development include TaurusOne, TaurusElite, TaurusNXT and others. The Company operates its businesses primarily in domestic market.

  • Revenue in HKD (TTM)475.06m
  • Net income in HKD-422.72m
  • Incorporated2012
  • Employees1.04k
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Immunotech Biopharm Ltd0.00-360.58m1.70bn211.00--9.08-----0.7007-0.70070.000.36340.00----0.00-38.88-37.42-50.88-45.48--------1.03-2.510.4327-------5.25---8.46--
Cryofocus Medtech Shanghai Co Ltd44.10m-104.99m1.74bn392.00--9.98--39.36-0.4391-0.43910.18440.7272------112,500.60--------75.83---258.23--4.08--0.0597--50.83--13.13------
Dawnrays Pharmaceutical (Holdings) Ltd1.24bn351.08m1.77bn1.14k5.050.57583.931.430.23360.23360.8252.050.31562.316.371,084,603.008.859.8911.3612.4954.6056.6928.0327.892.2628.890.040535.33-9.903.94-8.951.4163.922.00
Cutia Therapeutics148.21m-2.11bn1.87bn298.00--1.28--12.60-6.96-6.960.48754.78------497,349.40--------51.60---1,426.91--5.38--0.153--1,110.83---253.30------
SinoMab Bioscience Ltd1.47m-261.81m1.88bn215.00--5.59--1,277.42-0.2572-0.25720.00140.30760.0015----6,837.24-26.20-24.62-32.50-27.7230.92---17,810.33-4,451.74---11.480.604------14.45--106.81--
TOT Biopharm International Co Ltd840.68m-40.66m1.96bn551.00--2.64372.642.33-0.0561-0.05611.160.95690.58081.878.031,525,738.00-2.81-20.01-3.72-25.2173.5374.74-4.84-68.531.48-4.600.3348--76.5481.8824.36--21.04--
Frontage Holdings Corp2.03bn84.41m2.04bn1.76k24.480.76035.631.000.04090.04090.98061.320.46360.635.321,153,777.001.914.462.335.2830.1734.004.139.921.394.090.2960.003.7925.61-58.00-0.782640.43--
HighTide Therapeutics Inc0.00-1.01bn2.11bn66.00--2.56-----2.14-2.140.001.60------0.00--------------------0.0229-------393.76------
Abbisko Cayman Ltd20.53m-464.78m2.14bn258.00--1.00--104.34-0.7181-0.71810.03173.040.0083--1.4079,559.13-18.74---19.67--100.00---2,264.34------0.0177------12.92------
Laekna Inc0.00-397.19m2.23bn89.00--2.57-----3.29-3.290.002.22------0.00-------------------5.280.0655------52.81------
MicroPort CardioFlow Medtech Corp362.08m-507.81m2.29bn592.00--0.9115--6.33-0.2149-0.21490.15321.040.12052.783.67611,620.80-16.91-17.37-18.11-22.962.06-1.67-140.25-180.829.91-11.560.0293--33.94---3.77---14.16--
Golden Throat Holdings Group Co Ltd1.04bn269.41m2.40bn869.008.921.447.722.320.36440.36441.402.260.41814.821.851,191,409.0010.8811.0015.8515.6372.5772.7926.0224.672.4834.740.2183.15-3.096.73-11.0419.61-32.1338.94
Peijia Medical Ltd475.06m-422.72m2.49bn1.04k--1.02--5.23-0.6225-0.62250.69943.610.14730.77739.51456,789.50-13.11-34.08-14.94-36.9073.7671.62-88.99-448.756.92--0.0886--75.86--3.75------
Alphamab Oncology235.60m-226.79m2.59bn435.00--1.44--10.98-0.2359-0.23590.24551.870.10280.770519.34541,618.30-9.90-18.72-11.69-21.9474.75---96.26-415.555.55--0.1333--31.12--35.35---13.12--
Acotec Scientific Holdings Ltd510.30m15.60m2.59bn638.00159.191.8539.575.070.05190.05191.694.460.31360.72133.44799,843.800.9589--1.03--79.65--3.06--9.122.750.1529--19.80---79.35------
Biocytogen Pharmaceuticals Beijng Co Ltd772.06m-412.41m3.22bn1.07k--3.81--4.17-1.04-1.041.942.120.273216.215.74724,261.60-14.59---18.88--70.59---53.42--1.24-21.300.4077--34.28--36.38------
Data as of Mar 28 2024. Currency figures normalised to Peijia Medical Ltd's reporting currency: Hong Kong Dollar HKD

Institutional shareholders

0.00%Per cent of shares held by top holders
HolderShares% Held
FIL Investment Management (Hong Kong) Ltd.as of 15 Aug 202350.25m0.00%
Hillhouse Investment Management Ltd. (Hong Kong)as of 06 Dec 202340.74m0.00%
The Vanguard Group, Inc.as of 06 Jun 202416.98m0.00%
E Fund Management Co., Ltd.as of 31 Dec 202313.53m0.00%
UBS Asset Management (Hong Kong) Ltd.as of 29 Feb 202412.52m0.00%
Matthews International Capital Management LLCas of 06 Jun 202411.73m0.00%
FIL Investment Management (Singapore) Ltd.as of 15 Aug 20236.67m0.00%
BlackRock Fund Advisorsas of 06 Jun 20245.77m0.00%
Penghua Fund Management Co., Ltd.as of 31 Dec 20235.42m0.00%
Bosera Asset Management Co., Ltd.as of 31 Dec 20233.96m0.00%
More ▼
Data from 31 Dec 2023 - 13 Jun 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.